Riskpilot← Back to searchSign inGet full accessAbacus Medicine Pharmaceuticals ApS
APSActiveCVR 39192063Kalvebod Brygge 35Wholesale of pharmaceutical and medical goods · NACE 4646Est. 2017— employeeswww.aposave.com
Revenue 2024
DKK -64K
-12% vs 2023
EBITDA margin
100.0%
+12% vs 2023
Equity ratio
35.3%
Financial strength
Net profit 2024
DKK -2,4M
-276% vs 2023
| Revenue | DKK -64K | -12% |
| EBITDA | DKK -64K | +12% |
| Net profit | DKK -2,4M | -276% |
| Total assets | DKK 55,9M | -56% |
| Equity | DKK 19,7M | -11% |
| Employees | — | — |
Legal name
Abacus Medicine Pharmaceuticals ApS
CVR number
39192063
Legal form
Anpartsselskab
NACE code
4646 · Wholesale of pharmaceutical and medical goods
Founded
21. december 2017
Share capital
DKK 500.001
Employees
—
VAT registered
No
Audit selected
Yes
Last report
2024-12-31
Financial year
January – December
Signatory rights
Selskabet tegnes af direktøren.
Company purpose
Selskabets formål er at drive virksomhed med handel med medicin, herunder gennem datterselskaber, samt dertil knyttet virksomhed.
Address
Kalvebod Brygge 35
Email
customerservices@aposave.com
Website
www.aposave.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|
| Revenue | -62 | -212 | -63 | -43 | -36 | -73 | -64 |
| Staff expenses | -0 | -0 | -0 | -0 | -0 | -0 | -0 |
| EBITDA | -62 | -212 | -63 | -43 | -50 | -73 | -64 |
| Depreciation & amort. | -0 | -0 | -0 | -0 | -0 | -0 | -0 |
| EBIT | -62 | -212 | -63 | -43 | -50 | -73 | -64 |
| Net financials | 1.167 | 914 | 305 | 3.606 | -5.788 | 1.850 | -1.085 |
| Profit before tax | 1.105 | 702 | 241 | 3.562 | -5.838 | 1.777 | -1.149 |
| Tax | 245 | 154 | 53 | 784 | -1.284 | 391 | 1.287 |
| Net profit | 860 | 548 | 188 | 2.779 | -4.553 | 1.386 | -2.436 |
| Item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|
| Total assets | 21.534 | 22.586 | 58.495 | 88.225 | 103.224 | 127.181 | 55.940 |
| Equity | 15.336 | 15.884 | 22.572 | 25.351 | 20.797 | 22.183 | 19.747 |
| Long-term debt | 5.905 | 0 | 0 | 0 | 0 | 100.829 | 0 |
| Short-term debt | 293 | 6.702 | 35.923 | 62.875 | 82.426 | 4.170 | 36.193 |
| Total debt | 6.198 | 6.702 | 35.923 | 62.875 | 82.426 | 104.998 | 36.193 |
EBITDA margin
-6400000.0%
This company
15.8%
Market median
-40506429% vs market
20182024
Equity ratio
35.3%
This company
38.2%
Market median
+8% vs market
20182024
Return on equity
-12.3%
This company
18.4%
Market median
-167% vs market
20182024
Net profit margin
-243600000.0%
This company
8.1%
Market median
-3007407507% vs market
20182024
Asset turnover
-0.00×
This company
1.12×
Market median
-100% vs market
20182024
Debt / equity
1.83×
This company
0.62×
Market median
-195% vs market
20182024
- Annual report 2024Filed via CVR / Virk · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via CVR / Virk · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via CVR / Virk · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via CVR / Virk · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via CVR / Virk · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via CVR / Virk · Period 2019-01-01 – 2019-12-31
- Annual report 2018Filed via CVR / Virk · Period 2017-12-21 – 2018-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
FW Management | Management | 2017 | — | — |
No data on file.
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
ABACUS MEDICINE A/S | Company | 100.0% | 100.0% | 2017 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
AUGUSTINUS FONDENCHR. AUGUSTINUS FABRIKKER AKTIESELSKABABACUS MEDICINE A/S
Abacus Medicine Pharmaceuticals ApS (this company)Board members of Abacus Medicine Pharmaceuticals ApS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Flemming Wagner | Management | 0 companies |